Toxin and The Lower Third
Mr Ali Juma explores the use of botulinum toxin A in the lower third of the face
Mr Ali Juma explores the use of botulinum toxin A in the lower third of the face
Evidence for the inquiry into non-surgical cosmetic procedures in the UK must be submitted to the All-Party Parliamentary Group on Beauty, Aesthetics and Wellbeing (APPG BAW) by July 17.
A survey has indicated that only 22.5% of practitioners follow the recommended protocol for treating headaches with botulinum toxin.
The London Academy of Aesthetic Medicine has launched The Online Ultimate Toxin Course.
An Enforcement Notice on January 31 highlighting the rules and concerns around botulinum toxin advertising and other prescription-only medicines on social media has prompted a surge of enquiries to the Advertising Standards Authority (ASA).
Details of the Enforcement Notice relevant to all aesthetic clinics offering prescription-only medicines
Following positive phase 2 results from its ready-to-use liquid formulation botulinum toxin, global pharmaceutical company Galderma has received a manufacturing license from the Swedish Medical Products Agency (MPA) for a new state-of-the-art manufacturing facility at the Center of Excellence, located in Uppsala, Sweden.
A pilot study of 18 male patients has demonstrated an increase in hair density and thickness following botulinum toxin treatment.
Pharmaceutical company Galderma UK will be supporting the next webinar hosted by Aesthetics Media on October 14.